Close
What is CPIC?

The Clinical Pharmacogenetics Implementation Consortium (CPIC®) is an international consortium of individual volunteers and a small dedicated staff who are interested in facilitating use of pharmacogenetic tests for patient care.

One barrier to implementation of pharmacogenetic testing in the clinic is the difficulty in translating genetic laboratory test results into actionable prescribing decisions for affected drugs.

CPIC’s goal is to address this barrier to clinical implementation of pharmacogenetic tests by creating, curating, and posting freely available, peer-reviewed, evidence-based, updatable, and detailed gene/drug clinical practice guidelines (click here for all CPIC publications).  CPIC guidelines follow standardized formats, include systematic grading of evidence and clinical recommendations, use standardized terminology, are peer-reviewed, and are published in a leading journal (in partnership with Clinical Pharmacology and Therapeutics) with simultaneous posting to cpicpgx.org, where they are regularly updated.

CPIC started as a shared project between PharmGKB and the Pharmacogenomics Research Network (PGRN) in 2009. CPIC guidelines are indexed in PubMed as clinical guidelines, endorsed by ASHP and ASCPT, and referenced in ClinGen and PharmGKB

CPIC resources are freely available under a Creative Commons public domain license.
Read the license page for more details.

Team

Leader
Mary V. Relling, Pharm.D.
St. Jude Children’s Research Hospital, Memphis

Leader
Teri E. Klein, Ph.D.
Stanford University

Director
Kelly Caudle, Pharm.D., Ph.D.
St. Jude Children’s Research Hospital, Memphis

Steering Committee

Mary V. Relling, Pharm.D. St. Jude Children’s Research Hospital, Memphis

Teri E. Klein, Ph.D. Stanford University

Julie A. Johnson, Pharm.D. University of Florida

Dan M. Roden, M.D. Vanderbilt University

Rachel F. Tyndale, Ph.D. University of Toronto and CAMH

Scientific Advisory Board

Gwendolyn A. McMillin, Ph.D. ARUP Laboratories

Robert Nussbaum, M.D. University of California, San Francisco

Heidi Rehm, Ph.D. Partners Healthcare

Marc S. Williams, M.D. Geisinger

Brad Strock, Epic

Sandy Aronson, Partners Personalized Medicine

  • PharmGKB data used to establish a minimum genetic testing panel for psychiatry October 26, 2018
    The lack of standardization of which genes or alleles should be included in pharmacogenetic testing panels is a major barrier to the full implementation of pharmacogenomics in the clinic. In an effort to help clinicians select an appropriate pharmacogenetic test, Dr. Chad Bousman and Dr. Abdullah Al Maruf of the University of Calgary and Dr. […]
  • CPIC grant awarded October 4, 2018
    The co-PIs of the Clinical Pharmacogenetics Implementation Consortium (CPIC), Drs. Mary Relling of St. Jude Children's Research Hospital (SJCRH) and Teri Klein of Stanford University, will receive $5 million over the next 5 years from the National Institutes of Health (NIH) to continue and expand the project.  CPIC was created in 2009 as a partnership between […]
  • CYP2D6 genotype to phenotype standardization project - seeking feedback September 14, 2018
    The assignment of the CYP2D6 metabolizer phenotype based on a subject's genotype is an important aspect of clinical implementation of pharmacogenetics knowledge. Especially for CYP2D6, the genotype-inferred phenotypes vary across laboratories and guidelines. The goal of the CYP2D6 genotype to phenotype standardization project is to harmonize this translation. The following consensus was reached by a group […]
  • NHGRI/NCI survey on genomics education August 29, 2018
    The National Human Genome Research Institute (NHGRI), who are supportive of PharmGKB and CPIC, have teamed up with the National Cancer Institute (NCI) to survey research and healthcare professionals about genomics education. The results of this survey will help to determine the resource and training priorities for future genomics education.PharmGKB and CPIC are both actively […]
  • CPIC Guideline Update: Carbamazepine, Oxcarbazepine and HLA genotype February 14, 2018
    The CPIC Guideline for carbamazepine, oxcarbazepine and HLA genotype is now published in Clinical Pharmacology and Therapeutics. The accepted article can be viewed on the PharmGKB pages for carbamazepine and oxcarbazepine and on the CPIC website. Carbamazepine and oxcarbazepine are anticonvulsants which have been approved for treatment for epilepsy and, in the case of carbamazepine, trigeminal neuralgia. Patients with the HLA-A*31:01 and/or the […]